This is a definitive win for Hikma and a negative for Amarin, whose patent enforcement strategy is now weakened. Hikma's generic icosapent ethyl can continue marketing without inducement liability. Amarin faces reduced leverage for future patent claims. Traders should watch for potential follow-on skinny-label launches by other generics, which may pressure Amarin's Vascepa market share.
Price Chart
Executive Summary
The Supreme Court unanimously reversed the Federal Circuit and dismissed Amarin's induced-infringement suit against Hikma, holding that Hikma's skinny label, website, and press releases did not constitute 'active steps' to encourage infringement. The ruling removes a material patent-litigation overhang for Hikma's generic icosapent ethyl and sets a pro-generic precedent that narrows inducement liability for skinny-label drugs.
Court Ruling Details
Key Facts
- Supreme Court reversed Federal Circuit, dismissing Amarin's induced-infringement claim against Hikma for failure to state a claim.
- Unanimous opinion by Justice Jackson held that Hikma's label, website, and press releases did not constitute 'active steps' to encourage infringement.
- Court rejected the Federal Circuit's 'could be read as instruction' standard, requiring instead that the defendant 'actively encouraged infringement.'
- Hikma's skinny label was carved out per FDA requirements; its omission of the CV Limitation of Use was legally mandated, not an inducement.
- Hikma's press releases describing the drug as 'generic Vascepa' and citing sales figures were deemed too vague to support inducement.
- The ruling sets a pro-generic precedent that narrows inducement liability for skinny-label drugs across the industry.
Financial Impact
Removes risk of damages or injunction on Hikma's generic icosapent ethyl, which competes with Amarin's Vascepa (annual U.S. sales not stated in document).
Risk Factors
- Amarin could seek certiorari on a different theory or pursue other patent claims, but the unanimous SCOTUS ruling makes further litigation unlikely to succeed.
- The case was remanded for further proceedings consistent with the opinion, but the core inducement claim is dead.
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3axdbk8b-HKMPF |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 4, 2026 20w ago | Court Ruling | $19.29 $22.19 | ▲ +15.02% | ▲ +13.14% | $22.14 (+14.75%) |
Apr 20, 2026 27w ago | Court Ruling | $18.72 $21.26 | ▲ +13.59% | ▲ +7.75% | $22.14 (+18.27%) |
Apr 20, 2026 27w ago | Court Ruling | $18.72 $21.26 | ▲ +13.59% | ▲ +7.75% | $22.14 (+18.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers